Literature DB >> 6437698

Two-dimensional electrophoresis of human plasma apolipoproteins.

D L Sprecher, L Taam, H B Brewer.   

Abstract

The two-dimensional electrophoretic method with silver staining we describe better resolves plasma apolipoproteins (apo) than any procedure previously described. It can be used to screen for abnormalities in apoA-I, apoA-II, apoA-IV, apoC-II, apoC-III, apoD, apoE, and apoH. In addition, this is the first presentation of apoD and apoH on two-dimensional gels. This electrophoretic method will permit the quantification of plasma apolipoproteins by computer imaging. Such detailed analysis of the plasma apolipoproteins should provide a better understanding of apolipoprotein function and the role these apolipoproteins play in lipoprotein metabolism and the pathophysiology of dyslipoproteinemias and coronary artery disease.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6437698

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


  21 in total

1.  Clinical chemistry through Clinical Chemistry: a journal timeline.

Authors:  Robert Rej
Journal:  Clin Chem       Date:  2004-12       Impact factor: 8.327

2.  Surface rheology and adsorption kinetics reveal the relative amphiphilicity, interfacial activity, and stability of human exchangeable apolipoproteins.

Authors:  Victor Martin Bolanos-Garcia; Anne Renault; Sylvie Beaufils
Journal:  Biophys J       Date:  2007-11-09       Impact factor: 4.033

3.  The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice.

Authors:  Charles W Joyce; Marcelo J A Amar; Gilles Lambert; Boris L Vaisman; Beverly Paigen; Jamila Najib-Fruchart; Robert F Hoyt; Edward D Neufeld; Alan T Remaley; Donald S Fredrickson; H Bryan Brewer; Silvia Santamarina-Fojo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

4.  Apolipoprotein A1 Baltimore (Arg10----Leu), a new ApoA1 variant.

Authors:  J A Ladias; P O Kwiterovich; H H Smith; S K Karathanasis; S E Antonarakis
Journal:  Hum Genet       Date:  1990-04       Impact factor: 4.132

5.  Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency.

Authors:  S Yamashita; D L Sprecher; N Sakai; Y Matsuzawa; S Tarui; D Y Hui
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

6.  In vivo metabolism of proapolipoprotein A-I in Tangier disease.

Authors:  D Bojanovski; R E Gregg; L A Zech; M S Meng; C Bishop; R Ronan; H B Brewer
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

7.  Donor splice site mutation in the apolipoprotein (Apo) C-II gene (Apo C-IIHamburg) of a patient with Apo C-II deficiency.

Authors:  S S Fojo; U Beisiegel; U Beil; K Higuchi; M Bojanovski; R E Gregg; H Greten; H B Brewer
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

8.  Apolipoprotein CIISt. Michael. Familial apolipoprotein CII deficiency associated with premature vascular disease.

Authors:  P W Connelly; G F Maguire; J A Little
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

9.  Chylomicron-retinyl palmitate clearance in type I hyperlipidemic families.

Authors:  D L Sprecher; S L Knauer; D M Black; L A Kaplan; A A Akeson; M Dusing; D Lattier; E A Stein; M Rymaszewski; D A Wiginton
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

10.  Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients.

Authors:  G Baggio; E Manzato; C Gabelli; R Fellin; S Martini; G B Enzi; F Verlato; M R Baiocchi; D L Sprecher; M L Kashyap
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.